Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in the Nordic Countries, Denmark, Finland, Iceland, Norway and Sweden, or involving organisations from these countries.

Total search results: 1037 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Jennewein Biotechnologie–Chr. Hansen: investment, 202009– acquisition €310m on debt-free basis ANNOUNCED 2020-09-22
Lava Therapeutics–Novo Group: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Novo Ventures 2020-09-17
Lava Therapeutics–SEVERAL: investment, 202009 financing round Series C $83m co-led by Novo Ventures + Sanofi Ventures 2020-09-17
Umotif–SEVERAL: investment, 202009 financing round Series A £5m led by existing investor AlbionVC 2020-09-03
Scienion–Cellink: investment, 202008– acquisition €80m on cash/debt-free basis with €40m in shares + €40m in shares 2020-08-19
Genkyotex–Calliditas Therapeutics: investment, 202008– acquisition in two steps for €32.3m in cash + €55m milestones (contingent rights) ANNOUNCED 2020-08-13
F2G Ltd–Novo Group: investment, 202008 financing round totalling $60.8m incl exisiting investor Novo Ventures 2020-08-12
F2G Ltd–SEVERAL: investment, 202008 financing round $60.8m from new investor Cowen Healthcare Investments + existing investors 2020-08-12
Oasmia–Consilium: public relations, 202008 service existent by CSC 2020-08-10
Reapplix–Denmark (govt): investment, 202007 financing round totalling DKK150m ($22.6m) incl existing investor Vaekstfonden 2020-07-14
Reapplix–Lauxera Capital: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor Lauxera Capital Partners 2020-07-14
Reapplix–MK Ventures: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor MK Ventures 2020-07-14
Reapplix–North East Health Care: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor North East Health Care 2020-07-14
Reapplix–Novo Group: investment, 202007 financing round totalling DKK150m ($22.6m) incl existing investor Novo Holdings 2020-07-14
Reapplix–PERSON: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor Bo Jesper Hansen 2020-07-14
Reapplix–PERSON: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor Jan Struve 2020-07-14
Reapplix–SEVERAL: investment, 202007 financing round DKK150m ($22.6m) from new + existing investors 2020-07-14
Eir Ventures–Denmark (govt): investment, 202007 first closing totalling €76m incl investor Vaekstfonden 2020-07-10
Eir Ventures–EU (govt): investment, 202007 first closing totalling €76m incl investor EIF 2020-07-10
Eir Ventures–Novo Group: investment, 202007 first closing totalling €76m incl investor Novo Holdings 2020-07-10
Eir Ventures–Optimum Strategic Communications: public relations, 202007 service existent by Optimum 2020-07-10
Eir Ventures–SEVERAL: investment, 202007 first closing €76m from Saminvest + EIF + Vaekstfonden + Novo Holdings + private investors 2020-07-10
Eir Ventures–Sweden (govt): investment, 202007 first closing totalling €76m incl investor Saminvest 2020-07-10
VarmX–SEVERAL: investment, 202007 financing round Series B €32m co-led by Ysios Capital + INKEF Capital 2020-07-08
Resistell–EU (govt): grant, 202007 up to €2.5m grant + equity financing offer from EIC programme/fund 2020-07-03
Freeline Therapeutics–Novo Group: investment, 202006 financing round Series C final closing totalling $80m incl co-lead investor Novo Holdings A/S 2020-06-30
Freeline Therapeutics–SEVERAL: investment, 202006 financing round Series C final closing $80m (£61.2m) co-led by Novo Holdings + Eventide + Wellington 2020-06-30
JnJ–Bavarian Nordic: vaccine, 202006– supply $13.9m manufacturing + delivery of MVA-BN Filo Ebola vaccine to Janssen Vaccines & Prevention BV 2020-06-12
Corvidia Therapeutics–Goodwin Procter: legal services, 202006 supply service legal advisor to Cordivia for acquisition by Novo Nordisk 2020-06-11
Corvidia Therapeutics–JPMorgan Chase: financial services, 202006 supply service advisor to Cordivia for acquisition by Novo Nordisk 2020-06-11
Corvidia Therapeutics–Novo Group: investment, 202006 acquisition $725m upfront cash + $1.375b milestones cash by Novo Nordisk ANNOUNCED 2020-06-11
Novo Group–Davis Polk & Wardell: legal services, 202006 supply service legal advisor to Novo Nordisk for acquisition of Corvidia Therapeutics 2020-06-11
Bioqube Ventures–Genmab: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor Genmab 2020-06-10
Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al 2020-06-10
Valo Therapeutics–Scius Communications: public relations, 202006 supply service existent by Scius Communications 2020-06-08
NodThera–Novo Group: investment, 202006 financing round Series B totalling £44m ($55m) incl lead investor Novo Ventures 2020-06-03
NodThera–SEVERAL: investment, 202006 financing round Series B £44m ($55m) led by Novo Ventures 2020-06-03
Genmab–Rentschler: biologics contract manufacturing, 202005– collab expansion production of DuoBody products to new Rentschler US facility 2020-05-27
Exscientia–SEVERAL: investment, 202005 financing round Series C $60m led by Novo Holdings + incl Evotec + BMS + GT Healthcare Capital 2020-05-26
Kaiku Health–Elekta: investment, 202005 acquisition 100% of Kaiku Health by Elekta 2020-05-15
Calliditas Therapeutics–SEVERAL: investment, 202005–202006 private placement SEK82.9m with 924k common shares at SEK89.7/share outside US 2020-05-14
Calliditas Therapeutics–SEVERAL: investment, 202005–202007 US IPO $81m+$6.9m with w 8.3m+707k common shares as ADSs at Nasdaq Global Market 2020-05-14
Oncopeptides–SEVERAL: investment, 202005 directed share issue SEK1.414b ($144m) with 12.295m new shares at SEK115/share 2020-05-05
EnginZyme–SEVERAL: investment, 202004 financing round Series A €6.4m led by Sofinnova Partners 2020-04-22
EnginZyme–Sofinnova: investment, 202004 financing round Series A totalling €6.4m incl lead investor Sofinnova Industrial Biotech Fund 2020-04-22
Leo Pharma–Oneness Biotech: therapeutic antibody, 202004– license ww excl to FB825 $40m upfront + $530m milestones + royalties from Oneness + MBS 2020-04-15
Servier–Gorrissen Federspiel: legal services, 202004 supply service Gorrissen Federspiel legal advisor to Servier w regard to acquisition of Symphogen 2020-04-03
Servier–Lazard: financial services, 202004 supply service Lazard financial advisor to Servier w regard to acquisition of Symphogen 2020-04-03
Servier–McDermott Will & Emery: legal services, 202004 supply service MWE legal advisor to Servier w regard to acquisition of Symphogen 2020-04-03
Symphogen–Perkins Coie: legal services, 202004 supply service Perkins Coie legal advisor to Symphogen w regard to acquisition by Servier 2020-04-03
Symphogen–Plesner: legal services, 202004 supply service Plesner AP legal advisor to Symphogen w regard to acquisition by Servier 2020-04-03
Symphogen–Rothschild & Co: financial services, 202004 supply service Rothschild & Co financial advisor to Symphogen w regard to acquisition by Servier 2020-04-03
Symphogen–Servier: investment, 202004–202006 acquisition 100% €na 2020-04-03
Gilde Investment–SEVERAL: investment, 202003 first + final close of €416m Gilde Healthcare V fund incl investors Philips + Rabo Corp Investments 2020-03-31
Obi Medical–Roche: investment, 202003 acquisition of Obi Medical ApS by Roche 2020-03-31
Tempus Labs–Novo Group: investment, 202003 financing round Series G totalling $100m incl investor Novo Holdings 2020-03-13
Tempus Labs–SEVERAL: investment, 202003 financing round Series G $100m incl Baillie Gifford + Franklin Templeton + NEA + Novo Holdings + T Rowe Price 2020-03-13
Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS 2020-03-10
Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF 2020-03-10
Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical 2020-03-10
Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF 2020-03-10
Agilent–Visiopharm: image analysis software, 202003– collab co-marketing of Visiopharm’s AI-driven solutions for digital pathology 2020-03-02
Genmab–Genedata: bioinformatics, 202002 supply existent Genmab is existing customer of Genedata 2020-02-26
InstruNor–Fluidigm: investment, 202002 acquisition $7.2m with $5.2m in cash + $2m in stock 2020-02-26
Lundbeck–Genedata: bioinformatics, 202002 supply existent Lundbeck is existing customer of Genedata 2020-02-26
Merus–Genedata: bioinformatics, 202002 supply existent Merus is existing customer of Genedata 2020-02-26
Novo Group–Genedata: bioinformatics, 202002 supply existent Novo Nordisk is existing customer of Genedata 2020-02-26
Novo Group–Genedata: bioinformatics, 202002 supply existent Novozymes is existing customer of Genedata 2020-02-26
FinnGen–AbbVie: genomics, 202002 collab existent AbbVie is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–AstraZeneca: genomics, 202002 collab existent AstraZeneca is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Biogen: genomics, 202002 collab existent Biogen is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–BMS: genomics, 202002 collab existent BMS is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–GSK: genomics, 202002 collab existent GSK is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–JnJ: genomics, 202002– collab Janssen new industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Maze Therapeutics: genomics, 202002– collab Maze new industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Merck (US): genomics, 202002 collab existent MSD is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Pfizer: genomics, 202002 collab existent Pfizer is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Roche: genomics, 202002 collab existent Genentech is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Sanofi: genomics, 202002 collab existent Sanofi is industry partner of Finnish genome research project FinnGen 2020-02-25
Glycom–DSM: investment, 202002 acquisition of Glycom A/S by DSM for enterprise value of €765m 2020-02-21
Orphazyme–SEVERAL: investment, 202002 directed issue + private placement DKK745m (€100m) of 7m new + existing shares 2020-02-07
Servier–Saga Diagnostics: pharmacogenomic services, 202001–202201 collab extension 2y services usingSAGAsafe technology in cancer studies 2020-01-28
Blueprint Genetics–Quest Diagnostics: investment, 202001 acquisition €na by Quest Diagnostics 2020-01-22
HepaRegenix–Novo Group: investment, 202001 financing round Series B totalling €11m incl existing investor Novo Seeds 2020-01-21
HepaRegenix–SEVERAL: investment, 202001 financing round Series B €11m with BIVF + Novo Holdings + HTGF + Coparion + Ascenion 2020-01-21
Nanoform–Coulter Partners: recruitment services, 202001 supply service placement of Sally Langa as new head of US Sales at Nanoform 2020-01-21
Biograil–High-Tech Gründerfonds: investment, 202001 seed financing round totalling €3m (potentially up to €5m) incl lead investor HTGF 2020-01-15
Biograil–Megatrend Invest: investment, 202001 seed financing round totalling €3m (potentially up to €5m) incl co-investor Megatrend Invest A/S 2020-01-15
Biograil–OTHER: investment, 202001 seed financing round totalling €3m (potentially up to €5m) incl a Danish private healthcare investor 2020-01-15
Biograil–SEVERAL: investment, 202001 seed financing round €3m (potentially up to €5m) led by HTGF 2020-01-15
Biograil–Swiss Investment Group: investment, 202001 seed financing round totalling €3m (potentially up to €5m) incl co-investor Swiss Investment Group 2020-01-15
NorthSea Therapeutics–SEVERAL: investment, 202001 financing round Series B €36m led by new investor VenBio 2020-01-08
PharmAkea–Galecto Biotech: investment, 202001– merger €na with new Galecto Inc in US with operational HQ in Copenhagen ANNOUNCED 2020-01-07
VectivBio–Novo Group: investment, 202001 1st financing round totalling $35m incl Novo Holdings 2020-01-07
VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. 2020-01-07
Integrated Biotherapeutics–Novo Group: investment, 202001 investment $3.9m in IBT Vaccines by Novo REPAIR Impact Fund 2020-01-06
Pharma Omnium–Novo Group: investment, 202001 investment €7m by Novo REPAIR Impact fund into Mutabilis 2020-01-06
Savara–SEVERAL: investment, 201912– private placement $26.8m (with potential total proceeds of $75m) to institutional investors leb by Bain Capital LS 2019-12-20
CureVac–Genmab: investment, 201912 equity investment €20m by Genmab as part of strategic alliance 2019-12-19
Genmab–CureVac: mRNA-based antibody therapeutics, 201912– collab research + license agreem 5y $10m upfront using CureVac mRNA + Genmab Ab technologies 2019-12-19
1 2 3 4 5 6 7 8 9 10 11  next pagenext page



Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] Made Without Love 650x80px

» top